to Paula. for afternoon. time And call this taking you appreciate in. to listen you, the thank We joining you the everyone Thank
quarter, second cell therapy leverage company and the including transform device progresses make medical automated our the During and a platform. CAR-TXpress for the CDMO technologies, continued from semiautomated we and will we manufacturer proprietary through which cell a to to processing unique to cell market, gene
to process XX,XXX-square Sacramento. bringing suite designed the We good GMP practice current completion trials. to and at businesses and or clinical early-stage therapies feet for speed These in our the are novel GMP to of XX facility Class up manufacturing X suite are getting to close ReadyStart cleanrooms gene striving organizations cell
overall chain, priority manufacturer Our customers provide manage solutions the is to risk. increasing optimize with productivity and that supply
efforts whose to life therapy turnkey grade advertising cell started early-stage team expedite from and and research. non-GMP companies this have want We early need science their development to gene solution
which for potential to cGMP draw the on later interest availability, target We remains for this ReadyStart customers year. is have continued from state-of-art which unit
variety therapy smart storage public Indeed, banks cell for tailored been years, ThermoGenesis and XX cell the numerous top technologies revolutionary production advancement the technology and automated know, has sector. cell of and banking of products cryogenic for state-of-art for most ThermoGenesis the and cell spearheaded choice of globally. for you a private automated As over and has processing renowned
cryo while units nearly system utilized over system AXP clinical all has of blood CBUs, to approximately or grade BLA-approved has million storage Our core our handle XXX bioarchive been XX% for U.S. samples institutes globally. safeguarded well FDA
properties addition In acquired intellectual over in expertise valuable. gene years the we is the to cell therapies, our manufacturing extremely have
ongoing X XXXX, potential demonstrated cell The on driving behind myeloma. B-cell autologous growth to and approved in multiple emphasis force personalized CDMO the patients FDA therapeutics the of has CAR-T which our malignancy Since with therapies. gene the transition industry efficacy have is and and unprecedented
care to were of a may outperform expand as in ability demonstrated second-line initially the resort treatment, future. standard did suggests recent applications who CAR-T that the have for This alternative Although scope of authorized not to patients CAR-Ts final their respond for trials options. therapies
Recent expects starting FDA CAR-T for reports new potential XX year indicate with that industry each commercialization XX to approved in additional approvals therapies XXXX. the
an is the previously, and there of life-saving noted the these rise with therapies. medicine in regenerative CAR-T need increasing have treatment I FDA-approved therapies, for As production
a over are trial on and focused tumors. more and pipeline assets X,XXX are solid U.S. XXX there Presently, specifically and in development, companies cell there therapy worldwide research than targeting blood range exclusively clinical of wide
already in personalized enabled and gene provided promising R&D in is cell growth by remarkable prospects available the therapies exponential by alongside the This potential inherent therapies.
to of CDMO CAR-T $XXX,XXX for of one which cost therapeutics cost have preclinical in there currently attributed dose market. between as clinical of drug and the unprecedented for conducted, with times, many labor CAR-T cell just I an U.S. on the Moreover, manufacturing approximately Significantly, reliable per thousands making most services. high-quality some approved is trials X and therapies With GMP XX% noted facility being demand classes tends dose, expenses. expensive them to $XXX,XXX of to the exceeds and the $XXX,XXX
scale, developers to therapies from the enable dynamics, commercial cell these more will needs Given to tackle treatments. which benefit high-quality clinical these issue revolutionary producing patients a at of grade
have believe lowering potential that CAR-TXpress manufacturing strongly to rates recovery CAR-T enhancing for cell processing cost We the and other time, platform reduce and holds gene we the cell effectively considerably the and therapies.
solutions offer quality well as we manufacturing tissue system, services, other development, regulatory cell CDMO capacities with our and candidates compliance of development. therapeutic in processing cell different and manufacturing Through high-quality for as clients and stage development
platform time, integral therapies to cut mentioned, aspect XX%. with demonstrated ability cell which costs cell plan reduce an manufacturing by As up rate this its of CAR-TXpress gene other recovery potentially associated processing CAR-T proprietary enhancing significantly has and to high-efficient our and leveraging is and
our cells, portfolio, other inside provide cell and natural utilizing variety cells inducible to pluripotent stem chimeric such with the killer benefit receptor tumor cells clients stem in of therapy as the including extensive by we such Additionally, our of types and the T and cells, comprehensive intend TCR-T infiltrating a as mesenchymal cell expertise cells. antigen
to Our milestone allowing versatile a reach all-encompassing companies cGMP faster suite and projected ReadyStart more their solution, provide efficiently.
and affairs accelerate with the cGMP Additionally, of unit. our compliance manage while research product customers' commercialization on team's aspect we their focus development associated the our expertise them to should and quality in products, operating regulatory regulatory allowing
is highly the development. and research executive brings Biao additional Directors, business Xi biopharmaceutical years Dr. strong valuable the quarter, law. acumen, patent, Xu. legal and law of Dr. XX members IP in the field regarded more including to invited contributions extensive tax company. highly our in James with than second and Biao corporate drug And Their are to James two expertise life Board a In of and we science
the that, share call to quarter. the financial let for me to the results second Jeff key turn And Jeff? over with
